Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
719.8 INR | +0.01% | +3.20% | +31.90% |
May. 03 | Jubilant Pharmova Appoints CEO for Radiopharma Business | MT |
Apr. 25 | Jubilant Pharmova Subsidiary's Canadian Manufacturing Unit Gets Five Observations from US FDA | MT |
Sales 2022 | 61.3B 736M | Sales 2023 | 62.82B 754M | Capitalization | 44.42B 533M |
---|---|---|---|---|---|
Net income 2022 | 4.14B 49.67M | Net income 2023 | -610M -7.32M | EV / Sales 2022 | 1.37 x |
Net Debt 2022 | 22.03B 264M | Net Debt 2023 | 26.44B 317M | EV / Sales 2023 | 1.13 x |
P/E ratio 2022 |
14.9
x | P/E ratio 2023 |
-72.8
x | Employees | 5,778 |
Yield 2022 |
1.29% | Yield 2023 |
1.79% | Free-Float | 36.33% |
1 day | +0.01% | ||
1 week | +3.20% | ||
Current month | +6.95% | ||
1 month | +2.59% | ||
3 months | +18.73% | ||
6 months | +67.08% | ||
Current year | +31.90% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 46 | 17-05-22 | |
Chief Executive Officer | 37 | 17-05-22 | |
Arvind Chokhany
DFI | Director of Finance/CFO | 52 | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 67 | 81-12-31 | |
Chairman | 71 | 78-06-20 | |
Chief Executive Officer | 46 | 17-05-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 4 M€ | -4.41% | - | |
0.00% | 34 M€ | +4.26% | - | |
0.00% | 112 M€ | +5.51% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 719.8 | +0.01% | 23 460 |
24-05-16 | 719.8 | +0.55% | 36,805 |
24-05-15 | 715.8 | +4.09% | 32,406 |
24-05-14 | 687.7 | -0.04% | 18,512 |
24-05-13 | 688 | -1.38% | 17,622 |
Delayed Quote Bombay S.E., May 17, 2024 at 06:16 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+31.90% | 1.37B | |
+32.36% | 694B | |
+29.94% | 593B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+14.46% | 239B | |
+10.16% | 209B | |
-3.23% | 209B | |
+9.27% | 169B |
- Stock Market
- Equities
- JUBLPHARMA Stock